[Reactivity of peripheral blood lymphocytes in children with pituitary dwarfism treated with human growth hormone (author's transl)].
The study has aimed at investigating the blastic transformation of peripheral blood lymphocytes in patients with pituitary dwarfism before, during and after the treatment with human growth hormone. The reactivity of lymphocytes in vitro was studied in cultures stimulated with phytohemagglutinin-M of the Difco Company (PHA), in cultures stimulated with human growth hormone (HGH), and in cultures non-stimulated in vitro. The investigations were carried out in 34 patients with pituitary dwarfism at the age of 7 to 19 years. The control group was made up of 16 healthy children, 8 to 15 years old who had never been administered HGH. The patients were divided into groups according to the circumstance whether it was the first or the subsequent contact with HGH, and according to the periods at which the blood samples were collected during after therapy. It was found that the capability of lymphocytes to blastic transformation after stimulation with a specific stimulus (HGH) in patients with pituitary dwarfism in comparison with the reaction of healthy children is reduced (Fig. 2). The ability of the transformation of lymphocytes in this case shows selectivity towards the stimulus because the inhibiting of the response was noted only after the stimulation with HGH, but not after stimulation with PHA. During the treatment with HGH, allergization of the body appears; this is evidenced by the increase in the percentage of blastic cells in autotransformation (Fig. 1).
D000293:Adolescent; D000328:Adult; D002648:Child; D003864:Depression, Chemical; D004393:Dwarfism, Pituitary / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D013006:Growth Hormone / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology*; D008297:Male
D013006:Growth Hormone
Reaktywność limfocytów krwi obwodowej u dzieci z karłowatościa przysadkowa, leczonych ludzkim hormonem wzrostu